Research ExplorerPublicationsTranscatheter Mitral Valve Repair in Patients With Atrial Fu...

Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation

Standard

Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation. / Doldi, Philipp; Stolz, Lukas; Orban, Mathias; Karam, Nicole; Praz, Fabien; Kalbacher, Daniel; Lubos, Edith; Braun, Daniel; Adamo, Marianna; Giannini, Cristina; Melica, Bruno; Näbauer, Michael; Higuchi, Satoshi; Wild, Mirjam; Neuss, Michael; Butter, Christian; Kassar, Mohammad; Petrescu, Aniela; Pfister, Roman; Iliadis, Christos; Unterhuber, Matthias; Thiele, Holger; Baldus, Stephan; von Bardeleben, Ralph Stephan; Schofer, Niklas; Hagl, Christian; Petronio, Anna Sonia; Massberg, Steffen; Windecker, Stephan; Lurz, Philipp; Metra, Marco; Hausleiter, Jörg.

In: JACC-CARDIOVASC IMAG, Vol. 15, No. 11, 15.11.2022, p. 1843-1851.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Doldi, P, Stolz, L, Orban, M, Karam, N, Praz, F, Kalbacher, D, Lubos, E, Braun, D, Adamo, M, Giannini, C, Melica, B, Näbauer, M, Higuchi, S, Wild, M, Neuss, M, Butter, C, Kassar, M, Petrescu, A, Pfister, R, Iliadis, C, Unterhuber, M, Thiele, H, Baldus, S, von Bardeleben, RS, Schofer, N, Hagl, C, Petronio, AS, Massberg, S, Windecker, S, Lurz, P, Metra, M & Hausleiter, J 2022, 'Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation', JACC-CARDIOVASC IMAG, vol. 15, no. 11, pp. 1843-1851. https://doi.org/10.1016/j.jcmg.2022.05.009

APA

Doldi, P., Stolz, L., Orban, M., Karam, N., Praz, F., Kalbacher, D., Lubos, E., Braun, D., Adamo, M., Giannini, C., Melica, B., Näbauer, M., Higuchi, S., Wild, M., Neuss, M., Butter, C., Kassar, M., Petrescu, A., Pfister, R., ... Hausleiter, J. (2022). Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation. JACC-CARDIOVASC IMAG, 15(11), 1843-1851. https://doi.org/10.1016/j.jcmg.2022.05.009

Vancouver

Doldi P, Stolz L, Orban M, Karam N, Praz F, Kalbacher D et al. Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation. JACC-CARDIOVASC IMAG. 2022 Nov 15;15(11):1843-1851. https://doi.org/10.1016/j.jcmg.2022.05.009

Bibtex

@article{b8bd2b5ec9354eb98e0a0ef6a4706d30,
title = "Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation",
abstract = "BACKGROUND: Among patients with severe functional mitral regurgitation (FMR), atrial functional mitral regurgitation (aFMR) represents an underrecognized entity. Data regarding outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) in aFMR remain scarce.OBJECTIVES: The objective of this study was to analyze the outcome of aFMR patients undergoing M-TEER.METHODS: Using patients from the international EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry undergoing M-TEER for FMR, the authors analyzed baseline characteristics and 2-year outcomes in aFMR in comparison to non-aFMR and ventricular FMR. Additionally, the impact of right ventricular dysfunction (RVD) (defined as right ventricular to pulmonary artery uncoupling) on outcome after M-TEER was assessed.RESULTS: Among 1,608 FMR patients treated by M-TEER, 126 (7.8%) were categorized as aFMR. All 126 aFMR patients had preserved left ventricular function without regional wall motion abnormalities, left arterial dilatation and Carpentier leaflet motion type I. Procedural success (defined as mitral regurgitation ≤2+ at discharge) was 87.2% (P < 0.001) and New York Heart Association (NYHA) functional class significantly improved during follow-up (NYHA functional class III/IV: 86.5% at baseline to 36.6% at follow-up; P < 0.001). The estimated 2-year survival rate in aFMR patients was 70.4%. Two-year survival did not differ significantly between aFMR, non-aFMR, and ventricular FMR. Besides NYHA functional class IV, RVD was identified as a strong independent predictor for 2-year survival (HR: 2.82 [95% CI: 1.24-6.45]; P = 0.014).CONCLUSIONS: aFMR is a frequent cause of FMR and can be effectively treated with M-TEER to improve symptoms at follow-up. Advanced heart failure symptoms and RVD were identified as important risk factors for survival in aFMR patients.",
keywords = "Humans, Mitral Valve Insufficiency/diagnostic imaging, Mitral Valve/diagnostic imaging, Predictive Value of Tests, Cardiac Surgical Procedures/adverse effects, Ventricular Function, Left, Ventricular Dysfunction, Right, Treatment Outcome, Heart Valve Prosthesis Implantation/adverse effects",
author = "Philipp Doldi and Lukas Stolz and Mathias Orban and Nicole Karam and Fabien Praz and Daniel Kalbacher and Edith Lubos and Daniel Braun and Marianna Adamo and Cristina Giannini and Bruno Melica and Michael N{\"a}bauer and Satoshi Higuchi and Mirjam Wild and Michael Neuss and Christian Butter and Mohammad Kassar and Aniela Petrescu and Roman Pfister and Christos Iliadis and Matthias Unterhuber and Holger Thiele and Stephan Baldus and {von Bardeleben}, {Ralph Stephan} and Niklas Schofer and Christian Hagl and Petronio, {Anna Sonia} and Steffen Massberg and Stephan Windecker and Philipp Lurz and Marco Metra and J{\"o}rg Hausleiter",
note = "Copyright {\textcopyright} 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.",
year = "2022",
month = nov,
day = "15",
doi = "10.1016/j.jcmg.2022.05.009",
language = "English",
volume = "15",
pages = "1843--1851",
journal = "JACC-CARDIOVASC IMAG",
issn = "1936-878X",
publisher = "ELSEVIER SCIENCE INC",
number = "11",

}

RIS

TY - JOUR

T1 - Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation

AU - Doldi, Philipp

AU - Stolz, Lukas

AU - Orban, Mathias

AU - Karam, Nicole

AU - Praz, Fabien

AU - Kalbacher, Daniel

AU - Lubos, Edith

AU - Braun, Daniel

AU - Adamo, Marianna

AU - Giannini, Cristina

AU - Melica, Bruno

AU - Näbauer, Michael

AU - Higuchi, Satoshi

AU - Wild, Mirjam

AU - Neuss, Michael

AU - Butter, Christian

AU - Kassar, Mohammad

AU - Petrescu, Aniela

AU - Pfister, Roman

AU - Iliadis, Christos

AU - Unterhuber, Matthias

AU - Thiele, Holger

AU - Baldus, Stephan

AU - von Bardeleben, Ralph Stephan

AU - Schofer, Niklas

AU - Hagl, Christian

AU - Petronio, Anna Sonia

AU - Massberg, Steffen

AU - Windecker, Stephan

AU - Lurz, Philipp

AU - Metra, Marco

AU - Hausleiter, Jörg

N1 - Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PY - 2022/11/15

Y1 - 2022/11/15

N2 - BACKGROUND: Among patients with severe functional mitral regurgitation (FMR), atrial functional mitral regurgitation (aFMR) represents an underrecognized entity. Data regarding outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) in aFMR remain scarce.OBJECTIVES: The objective of this study was to analyze the outcome of aFMR patients undergoing M-TEER.METHODS: Using patients from the international EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry undergoing M-TEER for FMR, the authors analyzed baseline characteristics and 2-year outcomes in aFMR in comparison to non-aFMR and ventricular FMR. Additionally, the impact of right ventricular dysfunction (RVD) (defined as right ventricular to pulmonary artery uncoupling) on outcome after M-TEER was assessed.RESULTS: Among 1,608 FMR patients treated by M-TEER, 126 (7.8%) were categorized as aFMR. All 126 aFMR patients had preserved left ventricular function without regional wall motion abnormalities, left arterial dilatation and Carpentier leaflet motion type I. Procedural success (defined as mitral regurgitation ≤2+ at discharge) was 87.2% (P < 0.001) and New York Heart Association (NYHA) functional class significantly improved during follow-up (NYHA functional class III/IV: 86.5% at baseline to 36.6% at follow-up; P < 0.001). The estimated 2-year survival rate in aFMR patients was 70.4%. Two-year survival did not differ significantly between aFMR, non-aFMR, and ventricular FMR. Besides NYHA functional class IV, RVD was identified as a strong independent predictor for 2-year survival (HR: 2.82 [95% CI: 1.24-6.45]; P = 0.014).CONCLUSIONS: aFMR is a frequent cause of FMR and can be effectively treated with M-TEER to improve symptoms at follow-up. Advanced heart failure symptoms and RVD were identified as important risk factors for survival in aFMR patients.

AB - BACKGROUND: Among patients with severe functional mitral regurgitation (FMR), atrial functional mitral regurgitation (aFMR) represents an underrecognized entity. Data regarding outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) in aFMR remain scarce.OBJECTIVES: The objective of this study was to analyze the outcome of aFMR patients undergoing M-TEER.METHODS: Using patients from the international EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry undergoing M-TEER for FMR, the authors analyzed baseline characteristics and 2-year outcomes in aFMR in comparison to non-aFMR and ventricular FMR. Additionally, the impact of right ventricular dysfunction (RVD) (defined as right ventricular to pulmonary artery uncoupling) on outcome after M-TEER was assessed.RESULTS: Among 1,608 FMR patients treated by M-TEER, 126 (7.8%) were categorized as aFMR. All 126 aFMR patients had preserved left ventricular function without regional wall motion abnormalities, left arterial dilatation and Carpentier leaflet motion type I. Procedural success (defined as mitral regurgitation ≤2+ at discharge) was 87.2% (P < 0.001) and New York Heart Association (NYHA) functional class significantly improved during follow-up (NYHA functional class III/IV: 86.5% at baseline to 36.6% at follow-up; P < 0.001). The estimated 2-year survival rate in aFMR patients was 70.4%. Two-year survival did not differ significantly between aFMR, non-aFMR, and ventricular FMR. Besides NYHA functional class IV, RVD was identified as a strong independent predictor for 2-year survival (HR: 2.82 [95% CI: 1.24-6.45]; P = 0.014).CONCLUSIONS: aFMR is a frequent cause of FMR and can be effectively treated with M-TEER to improve symptoms at follow-up. Advanced heart failure symptoms and RVD were identified as important risk factors for survival in aFMR patients.

KW - Humans

KW - Mitral Valve Insufficiency/diagnostic imaging

KW - Mitral Valve/diagnostic imaging

KW - Predictive Value of Tests

KW - Cardiac Surgical Procedures/adverse effects

KW - Ventricular Function, Left

KW - Ventricular Dysfunction, Right

KW - Treatment Outcome

KW - Heart Valve Prosthesis Implantation/adverse effects

U2 - 10.1016/j.jcmg.2022.05.009

DO - 10.1016/j.jcmg.2022.05.009

M3 - SCORING: Journal article

C2 - 35842361

VL - 15

SP - 1843

EP - 1851

JO - JACC-CARDIOVASC IMAG

JF - JACC-CARDIOVASC IMAG

SN - 1936-878X

IS - 11

ER -